Clinically used estrogens differentially inhibit human aortic smooth muscle cell growth and mitogen-activated protein kinase activity.
about
Activation of GPER Induces Differentiation and Inhibition of Coronary Artery Smooth Muscle Cell ProliferationG-protein-coupled estrogen receptor as a new therapeutic target for treating coronary artery diseasePresence of oestrogen receptor type beta in human retinaEstrogen, aging and the cardiovascular systemEstrogen metabolite 2-methoxyestradiol induces apoptosis and inhibits cell proliferation and collagen production in rat and human leiomyoma cells: a potential medicinal treatment for uterine fibroids.Experimental benefits of sex hormones on vascular function and the outcome of hormone therapy in cardiovascular disease.Estrogenic compounds, estrogen receptors and vascular cell signaling in the aging blood vesselsPotential approaches to enhance the effects of estrogen on senescent blood vessels and postmenopausal cardiovascular disease.Extracellular 3',5'-cAMP-adenosine pathway inhibits glomerular mesangial cell growth.Resveratrol, a red wine constituent, blocks the antimitogenic effects of estradiol on human female coronary artery smooth muscle cells.Direct effects of estrogen on the vessel wall.Postmenopausal oestrogen replacement therapy and atherosclerosis: can current compounds provide cardiovascular protection?Cardiovascular protective effects of 17beta-estradiol metabolites.Candidate genes and mechanisms for 2-methoxyestradiol-mediated vasoprotection.Vascular Aging across the Menopause Transition in Healthy WomenPharmacologic effects of 2-methoxyestradiol on angiotensin type 1 receptor down-regulation in rat liver epithelial and aortic smooth muscle cellsOestrogen enhances cardiotoxicity induced by Sunitinib by regulation of drug transport and metabolism.Adenosine Attenuates Human Coronary Artery Smooth Muscle Cell Proliferation by Inhibiting Multiple Signaling Pathways That Converge on Cyclin D.2-Methoxyestradiol blocks the RhoA/ROCK1 pathway in human aortic smooth muscle cellsEndogenous estrogen attenuates hypoxia-induced pulmonary hypertension by inhibiting pulmonary arterial vasoconstriction and pulmonary arterial smooth muscle cells proliferation.Vascular actions of estrogens: functional implications.Estrogen-mediated protection in myocardial ischemia-reperfusion injury.Non-genomic regulation of vascular cell function and growth by estrogen.Estrogen and the cardiovascular system.2-Methoxyestradiol Reduces Angiotensin II-Induced Hypertension and Renal Dysfunction in Ovariectomized Female and Intact Male Mice.Dietary phytoestrogens present in soy dramatically increase cardiotoxicity in male mice receiving a chemotherapeutic tyrosine kinase inhibitor.Selected contribution: estrogen receptor-alpha gene transfer inhibits proliferation and NF-kappaB activation in VSM cells from female rats.High glucose abolishes the antiproliferative effect of 17beta-estradiol in human vascular smooth muscle cells.Treatment of vascular smooth muscle cells with estradiol and beta-adrenergic agonists has an additive effect on cAMP levels, but no additive effect on inhibition of collagen synthesis.Metabolite ligands of estrogen receptor-beta reduce primate coronary hyperreactivity.Oestrogen and vasculoprotection.17Beta-estradiol attenuates PDGF signaling in vascular smooth muscle cells at the postreceptor level.Conjugated linoleic acid isomers inhibit platelet-derived growth factor-induced NF-kappaB transactivation and collagen formation in human vascular smooth muscle cells.Molecular pathways of oestrogen receptors and β-adrenergic receptors in cardiac cells: Recognition of their similarities, interactions and therapeutic value.Spleen tyrosine kinase participates in Src-mediated migration and proliferation by PDGF-BB in rat aortic smooth muscle cells.Chrysanthemum boreale flower floral water inhibits platelet-derived growth factor-stimulated migration and proliferation in vascular smooth muscle cells.
P2860
Q24307625-C55B501A-05FD-4CCE-B7AB-7EE87750EBD3Q27001986-AE937A78-6F83-4DFF-A652-30304FDAEE43Q28367734-C4EE5BDD-F023-44CA-B0C1-C2821FD666ACQ28383144-D8742E5D-2248-4023-8EB3-725F5032FC12Q29347067-9AB3840E-982D-45C6-AB59-E4286364B659Q33572292-B90038F3-E2FA-4D84-90F8-F68DF9E69EA1Q33781367-CE881F81-32D5-49BE-95DD-44A4560073B0Q33786755-D0B24B81-2238-41F4-BE82-7A7FEC7FE46CQ33890867-5B119901-FD3A-4E56-A3DC-810B7D564B2DQ34113185-3AB77437-A1EC-47A9-94CB-94B6E8BFA4E5Q34165126-165774A2-DFEB-4CCD-9F1A-B26BD23E1170Q34232000-0EB0671C-B435-4540-99F3-3AA5FDD3EEACQ34377353-AE21E234-A7DC-40AB-9AE0-0D7F8220AD69Q34502795-8C98FD4C-64D2-4FF3-9EEF-67CB4A1CEA69Q35610656-A79114C9-9291-4DAF-85FC-C792AA4E700EQ35878038-902A25C1-6B5C-4067-A593-90894A74E605Q36027841-6DB0A8EF-2295-4E8B-9F08-3D90492BAB05Q36277823-62EF9449-0802-4391-A20E-AB2F3CE51845Q36751816-6B29F005-F9CB-44F3-ACD6-49EE07E96905Q36800936-83D1AEED-24F2-4037-8715-0DE4BDF956F2Q37088243-65C77456-680E-4DF5-9D0E-CFAAF8FD8B14Q37236040-A98A3902-43B3-4EAB-A64C-8653E25F9230Q37428590-31C2199C-B8F3-4D6E-B85F-B9F41E2A8289Q38000962-9211CC64-E136-4814-88AE-70F5137A7AEDQ38833622-5FD21E39-B29E-43BA-9942-53D6869D371BQ41981899-33EF933F-5DF6-4238-9243-2530B3557566Q43771449-EF8A008E-B316-4AD1-BBFF-F48AB3127BB9Q43908119-7B10A6AF-AD02-435F-BBDF-CE2CD6BDA044Q46651835-16AB75DB-B051-4720-909D-9FE84D1421FFQ46731901-897B3A7B-7456-4E2D-B69F-693AE3DB40EEQ46740969-3E0F1F17-76AB-4530-BDB2-665AE8476B60Q46755244-6E9E5FA1-16DD-4598-8068-9FEF80B9851DQ46761383-5D5ABCE9-BB89-4E1E-BE25-258084713D99Q47673235-379355D3-8C8C-4145-A47A-9D06CFE483C5Q50942151-AA5CD72E-A367-4C62-97E0-FF0B77BF115BQ53254399-DD01AC02-8044-48E2-A89B-6E0F843C6DDB
P2860
Clinically used estrogens differentially inhibit human aortic smooth muscle cell growth and mitogen-activated protein kinase activity.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Clinically used estrogens diff ...... vated protein kinase activity.
@ast
Clinically used estrogens diff ...... vated protein kinase activity.
@en
type
label
Clinically used estrogens diff ...... vated protein kinase activity.
@ast
Clinically used estrogens diff ...... vated protein kinase activity.
@en
prefLabel
Clinically used estrogens diff ...... vated protein kinase activity.
@ast
Clinically used estrogens diff ...... vated protein kinase activity.
@en
P2093
P356
P1476
Clinically used estrogens diff ...... vated protein kinase activity.
@en
P2093
D G Gillespie
E K Jackson
L C Zacharia
P J Keller
P304
P356
10.1161/01.ATV.20.4.964
P407
P577
2000-04-01T00:00:00Z